ACUGUARD is given orally once a month, at the minimum dosage of 22.5 mg/lb (50 mg/kg). Do not use the dosing schedule below when administering ACUGUARD to dogs, as it can result in an overdosage. Dosage Schedule: *Cats over 24 lbs should be administered the appropriate combination of tablets. Body Weight Spinosad Per Tablet (mg) Tablets Administered 2 to 4 lbs 90 One 4.1 to 6 lbs 140 One 6.1 to 12 lbs 270 One 12.1...
Store at 20 to 25°C (68 to 77°F), excursions permitted between 15 to 30°C (59 to 86°F).
www.vethical.com
www.fda.gov/AnimalVeterinary/SafetyHealth(spinosad)
Chewable Tablets
VETHICAL®
AcuGuard®
03A756
(spinosad)
Chewable Tablets
For information on dogs, see reverse side.
Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
ACUGUARD (spinosad) is available in four sizes of chewable flavored tablets for oral administration to cats and kittens according to their weight. Each chewable flavored tablet is formulated to provide a minimum spinosad dosage of 22.5 mg/lb (50 mg/kg). Spinosad is a member of the spinosyns class of insecticides, which are non-antibacterial tetracyclic macrolides. Spinosad contains two major factors, spinosyn A and spinosyn D, derived from the naturally occurring bacterium, Saccharopolyspora spinosa. Spinosyn A and spinosyn D have the chemical compositions 2-[(6-deoxy-2,3,4-tri-O-methyl-α-L mannopyranosyl)oxy]-13- [[5-(dimethylamino)tetrahydro-6 methyl-2H-pyran-2-yl]oxy]- 9-ethyl 2,3,3a,5a,5b,6,9,10,11,12,13,14,16a,16btetradecahydro- 14 methyl-1H-as-indaceno[3,2-d] oxacyclododecin-7,15-dione and 2 [(6-deoxy-2,3,4-tri-Omethyl- α-L-mannopyranosyl)oxy]-13-[[5 (dimethylamino) tetrahydro-6-methyl-2H-pyran-2-yl]oxy]-9-ethyl 2,3,3a,5a,5b, 6,9,10,11,12,13,14,16a,16b-tetradecahydro-4,14 dimethyl- 1H-as-indaceno[3,2-d]oxacyclododecin-7,15-dione, respectively.
ACUGUARD kills fleas and is indicated for the prevention and treatment of flea infestations (Ctenocephalides felis), for one month, on cats and kittens 14 weeks of age and older and two pounds of body weight or greater.
ACUGUARD is given orally once a month, at the minimum dosage of 22.5 mg/lb (50 mg/kg).
Do not use the dosing schedule below when administering ACUGUARD to dogs, as it can result in an overdosage.
| *Cats over 24 lbs should be administered the appropriate combination of tablets. | ||
Body Weight | Spinosad Per Tablet | Tablets |
2 to 4 lbs | 90 | One |
4.1 to 6 lbs | 140 | One |
6.1 to 12 lbs | 270 | One |
12.1 to 24* lbs | 560 | One |
Administer ACUGUARD with food for maximum effectiveness.
ACUGUARD is a chewable tablet that can be consumed by cats when offered by the owner just prior to or after feeding. Alternatively, ACUGUARD may be offered in food or administered like other tablet medications. ACUGUARD should be administered at monthly intervals.
If vomiting occurs within an hour of administration, redose with another full dose. If a dose is missed, administer ACUGUARD with food and resume a monthly dosing schedule.
Treatment with ACUGUARD may begin at any time of the year, preferably starting one month before fleas become active and continuing monthly through the end of flea season. In areas where fleas are common year-round, monthly treatment with ACUGUARD should continue the entire year without interruption.
To minimize the likelihood of flea reinfestations, it is important to treat all animals within a household with an approved flea protection product.
There are no known contraindications for the use of ACUGUARD.
Not for human use. Keep this and all drugs out of the reach of children.
Use with caution with concomitant extra-label use of ivermectin (see ADVERSE REACTIONS).
The safe use of ACUGUARD in breeding, pregnant, or lactating cats has not been evaluated.
In a well-controlled US field study, which included a total of 211 cats (139 treated with ACUGUARD and 72 treated with an active topical control once a month for 3 treatments), no serious adverse reactions were attributed to the administration of ACUGUARD.
Over the 90-day study period, all observations of potential adverse reactions were recorded. Reactions that occurred at an incidence > 1% within any of the 3 months of observations are presented in the following table. The most frequently reported adverse reaction in cats was vomiting.
Month 1 | Month 2 | Month 3 | ||||
ACUGUARD | Active | ACUGUARD | Active | ACUGUARD | Active | |
Vomiting | 14.4 | 1.4 | 14.8 | 1.4 | 13.6 | 4.5 |
Lethargy | 3.6 | 0.0 | 0.7 | 0.0 | 1.5 | 1.5 |
Anorexia | 2.2 | 0.0 | 0.7 | 0.0 | 2.3 | 1.5 |
Weight Loss | 1.4 | 0.0 | 0.7 | 0.0 | 3 | 0.0 |
Diarrhea | 1.4 | 1.4 | 0.7 | 2.9 | 2.3 | 1.5 |
Over the 3-month (3-dose) study, vomiting occurred on the day of or the day after at least one dose in 28.1% (39/139) of the cats treated with ACUGUARD and in 2.8% (2/72) of the cats treated with the active topical control. Three of the 139 cats treated with ACUGUARD vomited on the day of or the day after all three doses.
Two cats that received extra-label topical otic ivermectin on Day 1 of the field study developed lethargy on Day 1 after ACUGUARD administration on Day 0.
For technical assistance or to report an adverse drug experience, call 1-888-545-5973. Additional information can be found at www.vethical.com. For a complete listing of adverse reactions for spinosad reported to the Center for Veterinary Medicine, see Adverse Drug Experience Reports under www.fda.gov/AnimalVeterinary/SafetyHealth ProductSafetyInformation
The primary target of action of ACUGUARD in insects is an activation of nicotinic acetylcholine receptors (nAChRs). Spinosad does not interact with known binding sites of other nicotinic or GABAergic insecticides such as neonicotinides, fiproles, milbemycins, avermectins, and cyclodienes. Insects treated with spinosad show involuntary muscle contractions and tremors resulting from activation of motor neurons. Prolonged spinosad induced hyperexcitation results in prostration, paralysis, and flea death. The selective toxicity of spinosad between insects and vertebrates may be conferred by the differential sensitivity of the insect versus vertebrate nAChRs.
In a well-controlled laboratory study, ACUGUARD began to kill fleas 30 minutes after administration and demonstrated 98% effectiveness within 4 hours. ACUGUARD kills fleas before they can lay eggs. In a separate well-controlled laboratory study, ACUGUARD demonstrated 100% effectiveness on the first day following treatment and >90% effectiveness on Day 30.
If a severe environmental infestation exists, fleas may persist for a period of time after dose administration due to the emergence of adult fleas from pupae already in the environment.
In a field study conducted in households with existing flea infestations, flea count reductions of 97.5% were observed one month after the first treatment and 99.3% after three monthly treatments with ACUGUARD. Cats with pre-existing signs of flea allergy dermatitis showed improvement in erythema, papules, scaling, alopecia, dermatitis/pyodermatitis, and pruritus as a direct result of eliminating the fleas.
In a margin of safety study, ACUGUARD was administered orally to 14-week-old kittens at 1X, 3X, and 5X the upper half (75 – 100 mg/kg) of the therapeutic dose band for six monthly dosing intervals 28 days apart. Vomiting was observed across all groups, but was seen with greater frequency in cats in the treated groups; it did not increase with increasing doses. Loose stool was observed in all but the 3X treatment group. Food consumption was decreased in the 5X female cats. ACUGUARD was not associated with clinically significant changes in hematology, clinical chemistry, coagulation, or urinalysis parameters. Cats administered ACUGUARD once monthly for 6 months in the 3X and 5X dose groups demonstrated cytoplasmic vacuolation, consistent with phospholipidosis, in the liver, lung, and adrenal gland. The long term effects of phospholipidosis are unknown. The administration of ACUGUARD was not associated with any clinically significant, gross necropsy or histopathological changes.
In a well-controlled field study, ACUGUARD was administered safely in conjunction with other frequently used veterinary products, including tapeworm anthelmintics, antibiotics, and an approved heartworm preventative containing ivermectin. Hematology and clinical chemistry values were compared pre- and post-study and were unremarkable.
Store at 20 to 25°C (68 to 77°F), excursions permitted between 15 to 30°C (59 to 86°F).
ACUGUARD is available in four tablet sizes for use in cats: 90, 140, 270 or 560 mg. Each tablet size is available in color-coded packages of 6 tablets.
(spinosad)
Chewable Tablets
For information on cats, see reverse side.
Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
ACUGUARD (spinosad) is available in six sizes of chewable flavored tablets for oral administration to dogs and puppies according to their weight. Each chewable tablet is formulated to provide a minimum spinosad dosage of 13.5 mg/lb (30 mg/kg). Spinosad is a member of the spinosyns class of insecticides, which are non-antibacterial tetracyclic macrolides. Spinosad contains two major factors, spinosyn A and spinosyn D, derived from the naturally occurring bacterium, Saccharopolyspora spinosa. Spinosyn A and spinosyn D have the chemical compositions 2-[(6 deoxy-2,3,4-tri-O-methyl-α-L-mannopyranosyl)oxy]- 13-[[5 dimethylamino)-tetrahydro-6-methyl-2H-pyran- 2-yl]oxy]-9-ethyl 2,3,3a,5a,5b,6,9,10,11,12,13,14,16a,16b-tet radecahydro-14 methyl-1H-as-Indaceno[3,2-d]oxacyclodode cin-7, 15-dione and 2 [(6-deoxy-2,3,4-tri-O-methyl-α-Lmannopyranosyl) oxy]-13-[[5 dimethylamino)-tetrahydro-6-me thyl-2H-pyran-2-yl] oxy]-9-ethyl 2,3,3a,5a,5b,6,9,10,11,12,13, 14,16a,16b-tetradecahydro-4,14 dimethyl-1H-as- Indaceno[3,2-d] oxacyclododecin-7,15-dione, respectively.
ACUGUARD kills fleas and is indicated for the prevention and treatment of flea infestations (Ctenocephalides felis) for one month, on dogs and puppies 14 weeks of age and older and 3.3 pounds of body weight or greater.
ACUGUARD is given orally once a month, at the recommended minimum dosage of 13.5 mg/lb (30 mg/kg).
Do not use the dosing schedule below when administering ACUGUARD to cats, as it can result in an underdosage.
| * Dogs over 120 lbs should be administered the appropriate combination of tablets. | ||
Body Weight | Spinosad Per Tablet | Tablets |
3.3-4.9 lbs | 90 | One |
5 to 10 lbs | 140 | One |
10.1 to 20 lbs | 270 | One |
20.1 to 40 lbs | 560 | One |
40.1 to 60 lbs | 810 | One |
60.1 to 120* lb | 1620 | One |
Administer ACUGUARD with food for maximum effectiveness.
ACUGUARD is a chewable tablet and is readily consumed by dogs when offered by the owner just prior to feeding.
Alternatively, ACUGUARD may be offered in food or administered like other tablet medications. ACUGUARD should be administered at monthly intervals.
If vomiting occurs within an hour of administration, redose with another full dose. If a dose is missed, administer ACUGUARD with food and resume a monthly dosing schedule.
Treatment with ACUGUARD may begin at any time of the year, preferably starting one month before fleas become active and continuing monthly through the end of flea season. In areas where fleas are common year-round, monthly treatment with ACUGUARD should continue the entire year without interruption.
To minimize the likelihood of flea reinfestation, it is important to treat all animals within a household with an approved flea protection product.
There are no known contraindications for the use of ACUGUARD.
Not for human use. Keep this and all drugs out of the reach of children.
Serious adverse reactions have been reported following concomitant extra-label use of ivermectin with ACUGUARD
(see POST APPROVAL EXPERIENCE).
ACUGUARD is for use in dogs and puppies 14 weeks of age and older (see ANIMAL SAFETY).
Use with caution in breeding females (see ANIMAL SAFETY). Use with caution in dogs with pre-existing epilepsy (see ADVERSE REACTIONS). The safe use of ACUGUARD in breeding males has not been evaluated.
In a well-controlled US field study, which included a total of 470 dogs (330 dogs treated with ACUGUARD and 140 dogs treated with an active control), no serious adverse reactions were observed with ACUGUARD. All reactions were regarded as mild and did not result in any dog being removed from the study.
Over the 90-day study period, all observations of potential adverse reactions were recorded. Reactions that occurred at an incidence > 1% within any of the 3 months of observation are presented in the following table. The most frequently reported adverse reaction in dogs in the ACUGUARD and active control groups was vomiting. The occurrence of vomiting, most commonly within 48 hours after treatment, decreased with repeated doses of ACUGUARD.
| a This number (n=139) is less than the total number of dogs in the safety population for the active control group (n=140) because one dog joined the study late and was only dosed at Month 3. | ||||||
Month 1 | Month 2 | Month 3 | ||||
ACUGUARD | Active | ACUGUARD | Active | ACUGUARD | Active | |
Vomiting | 12.7 | 12.2 | 7.8 | 3.2 | 5.8 | 4.8 |
Decreased Appetite | 9.1 | 5.0 | 2.8 | 1.6 | 1.9 | 0.8 |
Lethargy | 7.6 | 5.0 | 3.5 | 4.0 | 1.2 | 0.8 |
Diarrhea | 6.7 | 5.0 | 4.3 | 0.8 | 1.2 | 0.0 |
Cough | 3.9 | 5.0 | 0.4 | 2.4 | 0.0 | 0.0 |
Polydipsia | 2.4 | 1.4 | 0.7 | 0.0 | 0.4 | 0.0 |
Vocalization | 1.8 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 |
Increased Appetite | 1.5 | 0.0 | 0.4 | 0.8 | 0.4 | 0.0 |
Erythema | 1.5 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 |
Hyperactivity | 1.2 | 1.4 | 0.0 | 0.0 | 0.4 | 0.0 |
Excessive Salivation | 1.2 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 |
In US and European field studies, no dogs experienced seizures when dosed with ACUGUARD at the therapeutic dose range of 13.5-27.3 mg/lb (30-60 mg/kg), including 4 dogs with pre-existing epilepsy. Four epileptic dogs that received higher than the maximum recommended dose of 27.3 mg/lb (60 mg/kg) experienced at least one seizure within the week following the second dose of ACUGUARD, but no seizures following the first and third doses. The cause of the seizures observed in the field studies could not be determined.
The following adverse reactions are based on post-approval adverse drug event reporting. The adverse reactions are listed in decreasing order of frequency: vomiting, depression/lethargy, anorexia, ataxia, diarrhea, pruritus, trembling, hypersalivation and seizures.
Following concomitant extra-label use of ivermectin with ACUGUARD, some dogs have experienced the following clinical signs: trembling/twitching, salivation/drooling, seizures, ataxia, mydriasis, blindness and disorientation.
Post approval experience continues to support the safety of ACUGUARD when used concurrently with heartworm preventatives according to label directions.
For technical assistance or to report an adverse drug experience, call 1-888-545-5973. Additional information can be found at www.vethical.com. For a complete listing of adverse reactions for spinosad reported to the Center for Veterinary Medicine, see Adverse Drug Experience Reports under www.fda.gov/AnimalVeterinary/SafetyHealth ProductSafetyInformation
The primary target of action of ACUGUARD in insects is an activation of nicotinic acetylcholine receptors (nAChRs). Spinosad does not interact with known insecticidal binding sites of other nicotinic or GABAergic insecticides such as neonicotinoids, fiproles, milbemycins, avermectins, and cyclodienes. Insects treated with spinosad show involuntary muscle contractions and tremors resulting from activation of motor neurons. Prolonged spinosad-induced hyperexcitation results in prostration, paralysis, and flea death. The selective toxicity of spinosad between insects and vertebrates may be conferred by the differential sensitivity of the insect versus vertebrate nAChRs.
In a well-controlled laboratory study, ACUGUARD began to kill fleas 30 minutes after administration and demonstrated 100% effectiveness within 4 hours. ACUGUARD kill fleas before they can lay eggs. If a severe environmental infestation exists, fleas may persist for a period of time after dose administration due to the emergence of adult fleas from pupae already in the environment. In field studies conducted in households with existing flea infestations of varying severity, flea reductions of 98.0% to 99.8% were observed over the course of 3 monthly treatments with ACUGUARD. Dogs with signs of flea allergy dermatitis showed improvement in erythema, papules, scaling, alopecia, dermatitis/pyodermatitis and pruritus as a direct result of eliminating the fleas.
ACUGUARD was tested in pure and mixed breeds of healthy dogs in well-controlled clinical and laboratory studies. No dogs were withdrawn from the field studies due to treatment-related adverse reactions.
In a dose tolerance study, ACUGUARD was administered orally to adult Beagle dogs at average doses of up to 100 mg/kg once daily for 10 consecutive days (16.7 times the maximum recommended monthly dose). Vomiting was seen in 5 of 6 treated dogs during the first 6 days of treatment, usually within 2.5 hours of dosing. Treated females lost weight early in the treatment period, but their weights were similar to control dogs by the end of the 24 day study. ACUGUARD was not associated with any clinically significant changes in hematology, blood coagulation or urinalysis parameters; however, mild elevations in ALT occurred in all dogs treated with ACUGUARD. By day 24, ALT values had returned to near baseline levels. Phospholipidosis (vacuolation) of the lymphoid tissue was seen in all dogs treated with ACUGUARD, the long-term effects of which are unknown.
In a margin of safety study, ACUGUARD was administered orally to 6-week-old Beagle puppies at average doses of 1.5, 4.4, and 7.4 times the maximum recommended dose at 28-day intervals over a 6-month period. Vomiting was observed across all groups, including the control. Increased vomiting was observed at elevated doses, usually within 1 hour following administration. Vomiting at all doses decreased over time and stabilized when puppies were 14 weeks of age. The average daily and total weight gains of treated dogs were smaller than control dogs and were dose dependent. ACUGUARD was not associated with clinically significant changes in hematology, clinical chemistry, coagulation or urinalysis parameters. Phospholipidosis (vacuolation) of the lymphoid tissue was seen in some dogs in the 4.4X group and all dogs in the 7.4X group. The long term effects of phospholipidosis are unknown. Treatment with ACUGUARD was not associated with any other clinically significant adverse clinical observations, gross necropsy or histopathological changes.
In a reproductive safety study, ACUGUARD was administered orally to female Beagles at 1.3 and 4.4 times the maximum recommended therapeutic dose every 28 days prior to mating, during gestation, and during a six-week lactation period. No treatment-related adverse effects were noted for conception rates in the dams, or for mortality, body temperature, necropsy, or histopathology findings for the dams or puppies. One dam from each treatment group experienced early pregnancy loss and one additional high dose dam aborted late term. The treated dams experienced more vomiting, especially at one hour post-dose, than the control dams. Puppies from dams treated at 1.3 times the maximum recommended therapeutic dose had lower body weights than puppies from control dams. Although puppy mortality between treated and control dams was not different, the puppies from the treated dams experienced more lethargy (4.4X group only), dehydration, weakness and felt cold to the touch (4.4X group only) than puppies from control dams.
A pilot study without a control group was conducted to analyze milk from three lactating dogs treated with an experimental formulation of spinosad at 1.5 times the maximum recommended dose administered at day 28 of gestation and 24 hours prior to parturition. The data demonstrated that spinosyns were excreted in the milk of these dogs. Mortality and morbidity were greatest in puppies from the dam with the highest spinosyns level in milk. The spinosad milk: reference plasma exposure ratio calculated from this study ranged from 2.2 to 3.5.
In well-controlled field studies, ACUGUARD was administered safely in conjunction with other frequently used veterinary products, such as vaccines, anthelmintics, antibiotics, steroids, flea and tick control products, anesthetics, NSAIDs, antihistamines, alternative/herbal remedies, shampoos, and prescription diets. Changes in hematology, clinical chemistry and urinalysis values were compared pre- and post-study and were unremarkable.
Store at 20-25°C (68 -77°F), excursions permitted between 15 to 30°C (59 to 86°F).
ACUGUARD is available in six tablet sizes for use in dogs: 90, 140, 270, 560, 810 or 1620 mg. Each tablet size is available in color coded packages of 6 tablets.
NADA #141-277, Approved by the FDA
Distributed by Vicar Operating, Inc.
12401 West Olympic Blvd.
Los Angeles, CA 90064
All trademarks are the property of their respective owners.
All rights reserved.
NDC 50386-4221-7 CA4221Y07AMC1
NDC 50386-4222-7 CA4222Y07AMC1
NDC 50386-4223-7 CA4223Y07AMC1
NDC 50386-4224-7 CA4224Y07AMC1
NDC 50386-4225-7 CA4225Y07AMC1
NDC 50386-4227-7 CA4227Y07AMC1
February 2013
PA086441AMB
AcuGuard®
(spinosad)
Chewable Tablets VETHICAL
AcuGuard®
03A722
ACUGUARD®-Cats
(spinosad)
Chewable Tablets
For information on dogs, see reverse side.
Your veterinarian has chosen to prescribe ACUGUARD to meet your flea treatment and prevention needs. Controlling fleas is important to the health of your cat. Please read this leaflet, which describes the proper use of ACUGUARD to treat and prevent flea infestations. If you have any questions about this information, please consult your veterinarian. Additional information can be found at www.vethical.com.
What is ACUGUARD?
ACUGUARD is a chewable, flavored tablet that you give to your cat to kill fleas and prevent flea infestations for one month. ACUGUARD is for monthly use in cats and kittens 14 weeks of age or older and 2 pounds of body weight or greater.
Why has my veterinarian prescribed ACUGUARD?
Your veterinarian has provided this medication to either prevent a flea infestation or to treat an existing flea infestation on your cat.
What should I discuss with my veterinarian regarding ACUGUARD for my cat?
Your veterinarian is your cat's healthcare expert and can make the best recommendation for medications for your cat. This includes the prevention and treatment of parasites such as fleas that may cause conditions that include flea allergy dermatitis, anemia, and other flea-related problems.
Key points of your discussion may include the following:
How should I give ACUGUARD to my cat?
Give ACUGUARD with food for maximum effectiveness. ACUGUARD is a chewable tablet that can be consumed by cats when offered just prior to or just after feeding. Alternatively, ACUGUARD may be offered in food or administered like other tablet medications.
Give ACUGUARD to your cat once a month. To help you remember the monthly dosing schedule, stick-on labels are included for your calendar.
What if I give more than the prescribed amount of ACUGUARD to my cat?
ACUGUARD has been tested in many types of cats, and no severe adverse reactions have been reported. At elevated dose rates, the most severe adverse reaction observed was increased vomiting and loose stool. In the event of possible overdose, contact your veterinarian, who is the healthcare expert for your cat.
Should I restrict either my cat's activity or contact with my cat after the tablet is consumed?
Since ACUGUARD is an oral formulation, you may maintain normal activities and interactions with your cat.
How quickly will ACUGUARD kill fleas?
In a laboratory study, ACUGUARD started to kill fleas within 30 minutes and killed 100% of the fleas within 24 hours. ACUGUARD kills fleas before they can lay eggs.
Does seeing fleas on my cat mean that the treatment is not working?
ACUGUARD kills fleas before they can lay eggs when used monthly according to the label directions. Remember that all animals in the household should be treated with an approved flea product to help control the flea population.
Female fleas that are living on animals produce eggs that fall from the animal into their surroundings. These eggs hatch within a week; larvae then emerge and spin cocoons to become pupae. The entire life cycle can be completed in as little as 3 weeks, with new adult fleas emerging from the pupae to jump onto your cat. Because each female flea can lay up to 50 eggs per day, there is potential for a large build-up of eggs, larvae and pupae, resulting in a constant supply of new adults emerging in the cat's environment.
Regardless of the product used to kill the fleas, the cat can continue to be exposed to the fleas that live in the environment. If these fleas jump onto the cat, they will be killed by ACUGUARD.
If you see fleas on your cat within a month after your cat receives ACUGUARD, it is most likely that these are new fleas that have recently emerged from pupae and jumped onto the cat. These new fleas will be killed before they can produce eggs that contaminate the environment.
Is it safe to give my cat ACUGUARD?
ACUGUARD has been demonstrated to be safe in cats when used according to label directions. Safety was shown in cats and kittens 14 weeks of age and older, in multiple laboratory studies and a field study in household cats. The safe use of ACUGUARD in breeding, pregnant, or lactating cats has not been evaluated.
What side effects might occur with ACUGUARD?
Like all medications, sometimes side effects may occur. In some cases, cats vomited after receiving ACUGUARD. If vomiting occurs within one hour of administration, redose with another full dose. Additional adverse reactions observed in studies were lethargy, decreased appetite, weight loss, and diarrhea.
Can other medications be given while my cat is taking ACUGUARD?
Yes, ACUGUARD has been given safely with a wide variety of products and medications. Your veterinarian should be made aware of all medications, including over-the-counter (OTC) medications, that you are giving to your cat. For heartworm prevention, use products that are specifically prescribed by your veterinarian.
How should ACUGUARD be stored?
Store at 68 to 77°F (20 to 25°C). Temporary periods of time outside of this range between 59 to 86°F (15 to 30°C) are permitted.
If you have questions regarding the use of this product, consult your veterinarian, your cat's healthcare expert. For technical assistance or to report an adverse drug reaction, call 1-888-545-5973. Additional information can be found at www.vethical.com.
Client (or dog owner) Information
ACUGUARD®-Dogs
(spinosad)
Chewable Tablets
For information on cats, see reverse side.
Your veterinarian has chosen to prescribe ACUGUARD to meet your flea treatment and prevention needs. Controlling fleas is very important to the health of your dog. Please read this leaflet, which describes the use of ACUGUARD to treat and prevent flea infestations. If you have any questions about this information, please consult your veterinarian. Additional information can be found at www.vethical.com.
What is ACUGUARD?
ACUGUARD is a chewable, flavored tablet that you give to your dog to kill fleas and prevent flea infestations for one month. ACUGUARD are for monthly use in dogs and puppies 14 weeks of age or older and 3.3 pounds of body weight or greater.
Why has my veterinarian prescribed ACUGUARD?
Your veterinarian has provided this medication to either prevent a flea infestation or to treat an existing infestation on your dog.
What should I discuss with my veterinarian regarding ACUGUARD for my dog?
Your veterinarian is your dog's healthcare expert and can make the best recommendation for medications for your dog. This includes the prevention and treatment of parasites such as fleas that may cause conditions that include flea allergy dermatitis, anemia, and other flea-related problems. Key points of your discussion may include the following:
How should I give ACUGUARD to my dog?
Give ACUGUARD with food for maximum effectiveness.
ACUGUARD is a chewable tablet and is readily consumed by dogs when offered by the owner just prior to feeding. Alternatively, ACUGUARD may be offered in food or administered like other tablet medications.
Give ACUGUARD to your dog once a month. To help you remember the monthly dosing schedule, stick-on labels are included for your calendar.
What if I give more than the prescribed amount of ACUGUARD to my dog?
ACUGUARD has been tested in many types of dogs, and no severe adverse reactions have been reported. At elevated dose rates, the most severe adverse reaction observed was increased vomiting. In the event of a possible overdose, contact your veterinarian, who is the healthcare expert for your dog.
Should I restrict either my dog's activity or contact with my dog after the tablet is consumed?
Since ACUGUARD is an oral formulation, you may maintain normal activities and interactions with your dog.
How quickly will ACUGUARD kill fleas?
In a laboratory study, ACUGUARD started to kill fleas within 30 minutes and killed 100% of the fleas within 4 hours. ACUGUARD kills fleas before they can lay eggs.
Does seeing fleas on my dog mean that the flea treatment is not working?
ACUGUARD kills fleas before they can lay eggs when used monthly according to the label directions. Remember that all animals in the household should be treated with an approved flea product to help control the flea population.
Female fleas that are living on animals produce eggs that fall from the animal into their surroundings. These eggs hatch within a week; larvae then emerge and spin cocoons to become pupae. The entire life cycle can be completed in as little as 3 weeks, with new adult fleas emerging from the pupae to jump onto your dog. Because each female flea can lay up to 50 eggs per day there is potential for a large build-up of eggs, larvae and pupae, resulting in a constant supply of new adults emerging in the dog's environment.
Regardless of the product used to kill the fleas, the dog can continue to be exposed to the fleas that live in the environment. When these fleas jump onto the dog, they will be quickly killed by ACUGUARD.
If you see fleas on your dog within a month after your dog receives ACUGUARD, it is most likely that these are new fleas that have very recently emerged from pupae and jumped onto the dog. These new fleas will quickly be killed before they can produce eggs that contaminate the environment.
Is it safe to give my dog ACUGUARD?
ACUGUARD have been demonstrated to be safe in pure and mixed breeds of healthy dogs when used according to label directions. Safety was shown in puppies 14 weeks of age and older and adult dogs in both laboratory studies and clinical field studies. You should discuss the use of ACUGUARD with your veterinarian prior to use if your dog has a history of epilepsy (seizures).
Is it safe to give my breeding dogs ACUGUARD?
Use with caution in breeding females. You should discuss the use of ACUGUARD with your veterinarian prior to use in breeding females. Safe use of ACUGUARD in male dogs intended for breeding has not been evaluated.
What side effects might occur with ACUGUARD?
Like all medications, sometimes side effects may occur. In some cases, dogs vomited after receiving ACUGUARD. If vomiting occurs within an hour of administration, redose with another full dose. During clinical studies, no severe or prolonged vomiting occurred. Additional adverse reactions observed in the clinical studies were decreased appetite, lethargy or decreased activity, diarrhea, cough, increased thirst, vocalization, increased appetite, redness of the skin, hyperactivity and excessive salivation. These reactions were regarded as mild and did not result in any dog being removed from the studies.
Since the introduction of ACUGUARD, additional side effects reported are incoordination, itching, trembling and seizures.
Can other medications be given while my dog is taking ACUGUARD?
Yes, ACUGUARD have been given safely with a wide variety of products and medications. Your veterinarian should be made aware of all products that you administered and/or intend to administer to your dog. For heartworm prevention, use products that are specifically prescribed by your veterinarian.
How should ACUGUARD be stored?
Store at 68-77°F (20-25°C). Temporary periods of time outside of this range between 59-86°F (15-30°C) are permitted.
If you have questions regarding the use of this product, consult your veterinarian, your dog's healthcare expert. For technical assistance or to report an adverse drug reaction, call 1-888-545-5973. Additional information can be found at www.vethical.com.
All trademarks are the property of their respective owners. All rights reserved.
NDC 50386-4221-7 CA4221Y07AMC1
NDC 50386-4222-7 CA4222Y07AMC1
NDC 50386-4223-7 CA4223Y07AMC1
NDC 50386-4224-7 CA4224Y07AMC1
NDC 50386-4225-7 CA4225Y07AMC1
NDC 50386-4227-7 CA4227Y07AMC1
February 2013 PA086441AMA
VETHICAL® AcuGuard® (spinosad)
FOR CATS
2-4 lbs
FOR DOGS
3.3-4.9 lbs
6
CHEWABLE
TABLETS
90 mg
KILLS FLEAS
FAST ACTING
ONCE A MONTH
AcuGuard®
(spinosad)
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
AcuGuard® (spinosad)
CAUTION: Federal (USA) law restricts this drug to use
by or on the order of a licensed veterinarian.
KILLS FLEAS AND
PREVENTS INFESTATIONS
For use in dogs and puppies 14 weeks of age and older.
For use in cats and kittens 14 weeks of age or older.
FOR CATS & DOGS
2-4 lbs
90 mg Chewable Tablets
3.3-4.9 lbs
90 mg Chewable Tablets
VETHICAL® AcuGuard® (spinosad)
FOR CATS
4.1-6 lbs
FOR DOGS
5-10 lbs
6
CHEWABLE
TABLETS
140 mg
KILLS FLEAS
FAST ACTING
ONCE A MONTH
AcuGuard®
(spinosad)
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
AcuGuard® (spinosad)
CAUTION: Federal (USA) law restricts this drug to use
by or on the order of a licensed veterinarian.
KILLS FLEAS AND
PREVENTS INFESTATIONS
For use in dogs and puppies 14 weeks of age and older.
For use in cats and kittens 14 weeks of age or older.
FOR CATS & DOGS
4.1-6 lbs
140 mg Chewable Tablets
5-10 lbs
140 mg Chewable Tablets
VETHICAL® AcuGuard® (spinosad)
FOR CATS
6.1-12 lbs
FOR DOGS
10.1-20 lbs
6
CHEWABLE
TABLETS
270 mg
KILLS FLEAS
FAST ACTING
ONCE A MONTH
AcuGuard®
(spinosad)
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
AcuGuard® (spinosad)
CAUTION: Federal (USA) law restricts this drug to use
by or on the order of a licensed veterinarian.
KILLS FLEAS AND
PREVENTS INFESTATIONS
For use in dogs and puppies 14 weeks of age and older.
For use in cats and kittens 14 weeks of age or older.
FOR CATS & DOGS
6.1-12 lbs
270 mg Chewable Tablets
10.1-20 lbs
270 mg Chewable Tablets
VETHICAL® AcuGuard® (spinosad)
FOR CATS
12.1-24 lbs
FOR DOGS
20.1-40 lbs
6
CHEWABLE
TABLETS
560 mg
KILLS FLEAS
FAST ACTING
ONCE A MONTH
AcuGuard®
(spinosad)
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
AcuGuard® (spinosad)
CAUTION: Federal (USA) law restricts this drug to use
by or on the order of a licensed veterinarian.
KILLS FLEAS AND
PREVENTS INFESTATIONS
For use in dogs and puppies 14 weeks of age and older.
For use in cats and kittens 14 weeks of age or older.
FOR CATS & DOGS
12.1-24 lbs
560 mg Chewable Tablets
20.1-40 lbs
560 mg Chewable Tablets
VETHICAL® AcuGuard® (spinosad)
FOR DOGS
40.1-60 lbs
6
CHEWABLE
TABLETS
810 mg
KILLS FLEAS
FAST ACTING
ONCE A MONTH
AcuGuard®
(spinosad)
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
AcuGuard® (spinosad)
CAUTION: Federal (USA) law restricts this drug to use
by or on the order of a licensed veterinarian.
KILLS FLEAS AND
PREVENTS INFESTATIONS
For use in dogs and puppies 14 weeks of age and older.
FOR
DOGS
40.1-60 lbs
810 mg Chewable Tablets
VETHICAL® AcuGuard® (spinosad)
FOR DOGS
60.1-120 lbs
6
CHEWABLE
TABLETS
1620 mg
KILLS FLEAS
FAST ACTING
ONCE A MONTH
AcuGuard®
(spinosad)
CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.
AcuGuard® (spinosad)
CAUTION: Federal (USA) law restricts this drug to use
by or on the order of a licensed veterinarian.
KILLS FLEAS AND
PREVENTS INFESTATIONS
For use in dogs and puppies 14 weeks of age and older.
FOR
DOGS
60.1-120 lbs
1620 mg Chewable Tablets
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| SPINOSAD | ACTIVE INGREDIENT | XPA88EAP6V | 3 | |
| SPINOSAD | ACTIVE MOIETY | XPA88EAP6V | 3 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 3 | |
| CROSCARMELLOSE SODIUM | INACTIVE INGREDIENT | M28OL1HH48 | 3 | |
| HYDROXYPROPYL CELLULOSE | INACTIVE INGREDIENT | RFW2ET671P | 3 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 3 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 3 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 50386-4221 | 50386-4221-7, 50386-4221-8 |
| 50386-4222 | 50386-4222-7, 50386-4222-8 |
| 50386-4223 | 50386-4223-7, 50386-4223-8 |
| 50386-4224 | 50386-4224-7, 50386-4224-8 |
| 50386-4225 | 50386-4225-7, 50386-4225-8 |
| 50386-4227 | 50386-4227-7, 50386-4227-8 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER, FOR SUSPENSION / ORAL | 120 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING / ORAL | 68 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / ORAL | 25 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 9 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, FILM COATED / ORAL | 330 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED PELLETS / ORAL | 69 mg | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | CAPSULE, DELAYED RELEASE / ORAL | 150 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, SOLUBLE / ORAL | 2 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE / ORAL | 1190 mg | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET, FILM COATED / ORAL | 131.67 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | GRANULE / ORAL | 29520 mg | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | SOLUTION / TOPICAL | 200 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / TOPICAL | 104 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, FOR SUSPENSION / ORAL | 131 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / RESPIRATORY (INHALATION) | 0.13 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TROCHE / ORAL | 315 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | GRANULE / ORAL | 150 mg | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | LOTION / TOPICAL | 6 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, ORALLY DISINTEGRATING / ORAL | 184 mg | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET / ORAL | 230 mg | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | CAPSULE, EXTENDED RELEASE / ORAL | 204 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | DROPS / ORAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE / ORAL | 5000 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE, FOR SUSPENSION / ORAL | 14 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, DELAYED RELEASE / ORAL | 3.2 mg | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | SUSPENSION / ORAL | 100 mg | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET / SUBLINGUAL | 1 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / VAGINAL | 8 %w/w | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 127 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED / ORAL | 3 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, SUGAR COATED / ORAL | NA | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | INSERT / VAGINAL | 69 mg | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | CAPSULE / ORAL | 120 mg | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | GEL / TOPICAL | 222 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | POWDER, FOR SOLUTION / ORAL | 690 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | LOZENGE / ORAL | 120 mg | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | POWDER, FOR SUSPENSION / ORAL | 200 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, COATED / ORAL | 224 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | PELLET / ORAL | 162 mg | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | FILM, EXTENDED RELEASE / TRANSDERMAL | 19 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER, FOR SOLUTION / ORAL | 280 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / BUCCAL | 3 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | TABLET, DELAYED RELEASE PARTICLES / ORAL | 64 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, ORALLY DISINTEGRATING / ORAL | 187 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE, EXTENDED RELEASE / ORAL | 117 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SUSPENSION, EXTENDED RELEASE / ORAL | 71 mg | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 187.6 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | GRANULE, FOR SUSPENSION / ORAL | 278 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, EXTENDED RELEASE / ORAL | 168 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / SUBLINGUAL | 17.5 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE / ORAL | 254 mg | ||
| CROSCARMELLOSE SODIUM | CROSCARMELLOSE SODIUM | M28OL1HH48 | CAPSULE, COATED PELLETS / ORAL | 198 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, EXTENDED RELEASE / ORAL | 1246 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, COATED PELLETS / ORAL | 456 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, CHEWABLE / ORAL | 127 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| HYDROXYPROPYL CELLULOSE | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | RFW2ET671P | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 39.2 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / BUCCAL | 17.5 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE / ORAL | 629 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Spinosad | SPINOSAD | Cipher Pharmaceuticals Inc. | 16a95039-0df7-45d5-8b51-bbc81443fea3 | 2026-03-04 | Warnings, Adverse reactions | SPINOSAD |
| Natroba | SPINOSAD | Cipher Pharmaceuticals Inc. | 72cf38f4-9ef4-4b0e-b085-b02f399e2592 | 2026-03-04 | Warnings, Adverse reactions | SPINOSAD |
| Spinosad | SPINOSAD | Allegis Pharmaceuticals, LLC | 8e87bd3b-db25-4e97-bf57-96c875f67ce1 | 2025-12-17 | Warnings, Adverse reactions | SPINOSAD |
| Spinosad | SPINOSAD | ParaPRO LLC | 0d6e2507-3669-441e-b5ba-86087fd2955d | 2024-01-29 | Warnings, Adverse reactions | SPINOSAD |
| Natroba | SPINOSAD | ParaPRO LLC | fa90ccc8-2df0-49f7-8878-2b33e34cd272 | 2021-04-28 | Warnings, Adverse reactions | SPINOSAD |
Adverse event summaries are temporarily unavailable. Other product information remains available.